Neumentum, Inc

Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company with 4 novel non-opioid products in development to treat pain, both in the U.S. and around the world. The Company aims to address shortfalls of current pain management treatments by developing and commercializing effective and safe, non-opioid options without the risks of abuse, misuse, and diversion seen with opioids, or the opioid-induced side effects, including potentially life-threatening respiratory depression. Neumentum has two lead product candidates being developed to directly help address the opioid crisis. NTM-001, currently in Phase 3, is an IV formulation of Toradol (ketorolac) with Phase I results showing that it may provide consistent, steady blood plasma levels of ketorolac over 24 hours and durable analgesic effect. NTM-001 has the potential to be the first-ever NSAID approved for continuous infusion. NTM-006, a Phase 2 novel oral analgesic with a target indication for acute and chronic pain that has demonstrated meaningful analgesia in a Phase 2a Proof of Concept study, was licensed from Janssen Pharmaceuticals NV and McNeil Consumer Pharmaceuticals Co, both part of the Johnson & Johnson Family of Companies. Neumentum is led by an executive team of biotech and pharmaceutical experts who have extensive experience in pain and neurology, from drug development through commercialization. For more information, visit